Status:
COMPLETED
Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
HDL from patients with type 2 diabetes show a significant reduction of their endothelium-dependent vasodilatory effect. The primary objective of the study is to analyze whether treatment with glitazo...
Detailed Description
The study will be performed as follows: At baseline, before initiating glitazone treatment, clinical data will be recorded and blood samples will be obtained for biological measurements (blood glucos...
Eligibility Criteria
Inclusion
- patients with type 2 diabetes treated by oral antidiabetic agents (except glitazones) and/or insulin
- age\> 18 years
- HbA1c \> 6.5%
Exclusion
- renal failure
- heart failure
- primary hyperlipidemia
- pregnancy
- treatment that may modify lipid metabolism (glucocorticoids, oestrogens, retinoids, HIV antiviral drugs)
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00953498
Start Date
October 1 2007
End Date
March 1 2012
Last Update
September 2 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service Endocrinologie-diabétologie, Hôpital du Bocage CHU
Dijon, France, 21000